Erasmus School of Health Policy & Management
Endowed professor | Health Technology Assessment (HTA)
- retel@eshpm.eur.nl
More information
Work
- L. F. van Schaik, E. G. Engelhardt, E. A. Wilthagen, N. Steeghs, A. Fernández Coves, M. A. Joore, W. H. van Harten & V. P. Retèl (2024) - Factors for a broad technology assessment of comprehensive genomic profiling in advanced cancer, a systematic review - Critical Reviews in Oncology/Hematology, 202 - doi: 10.1016/j.critrevonc.2024.104441 - [link]
- Joost G.E. Verbeek, Leyla Azarang, Luis Pilli, Vincent M.T. de Jong, Agnes Jager, Sabine C. Linn, Valesca Retel & Wim Van Harten (2024) - High-dose chemotherapy for patients with stage III breast cancer with homologous recombination deficiency: a discrete choice experiment among healthcare providers - Acta Oncologica, 63, 701-709 - doi: 10.2340/1651-226X.2024.40276
- Astrid Kramer, Marjolein J.E. Greuter, Suzanna J. Schraa, Geraldine R. Vink, Jillian Phallen, Victor E. Velculescu, Gerrit A. Meijer, Daan van den Broek, Miriam Koopman, Jeanine M.L. Roodhart, Remond J.A. Fijneman, Valesca P. Retèl & Veerle M.H. Coupé (2024) - Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer - Therapeutic Advances in Medical Oncology, 16 - doi: 10.1177/17588359241266164 - [link]
- Michail Ignatiadis, Fiorita Poulakaki, Tanja Spanic, Etienne Brain, Denis Lacombe, Gabe S. Sonke, Anne Vincent-Salomon, Frederieke Van Duijnhoven, Icro Meattini, Orit Kaidar-Person, Philippe Aftimos, Frederic Lecouvet, Fatima Cardoso, Valesca P. Retèl & David Cameron (2024) - EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe - European Journal of Cancer, 207 - doi: 10.1016/j.ejca.2024.114156 - [link]
- Pien Lof, Neeltje J. van Soolingen, Jurgen M.J. Piek, Johanna W.M. Aarts, Valesca P. Retèl, Maarten Bukman, Carolina H. Smorenburg, Willemien J. van Driel, Frédéric Amant, Johannes W. Trum & Christianne A.R. Lok (2024) - Preferences and considerations for interval cytoreductive surgery in advanced ovarian cancer: The patient's perspective - Gynecologic Oncology, 187, 227-234 - doi: 10.1016/j.ygyno.2024.05.018 - [link]
- Zakile A. Mfumbilwa, Martijn J.H.G. Simons, Bram Ramaekers, Valesca P. Retèl, Joanne M. Mankor, Harry J.M. Groen, Joachim G.J.V. Aerts, Manuela Joore, Janneke A. Wilschut & Veerle M.H. Coupé (2024) - Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy - PharmacoEconomics, 42 (4), 419-434 - doi: 10.1007/s40273-023-01344-w - [link]
- Michael Schlander, Wim van Harten, Valesca P. Retèl, Phu Duy Pham, Julie M. Vancoppenolle, Jasper Ubels, Olaya Seoane López, Camila Quirland, Felipe Maza, Eline Aas, Bernd Crusius, Agustín Escobedo, Nora Franzen, Jeanette Fuentes-Cid, Diego Hernandez, Karla Hernandez-Villafuerte, Iva Kirac, Artus Paty, Thierry Philip, Sigbjørn Smeland, Richard Sullivan, Elena Vanni, Sinisa Varga, Thomas Vermeulin & Rachel D. Eckford (2024) - The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research directions - The Lancet Oncology, 25 (4), e152-e163 - doi: 10.1016/S1470-2045(23)00636-8 - [link]
- Renske M.T. Ten Ham, Maartje W. Rohaan, Inge Jedema, Rob Kessels, Wim Stegeman, Walter Scheepmaker, Bastiaan Nuijen, Cynthia Nijenhuis, Melanie Lindenberg, Troels Holz Borch, Tine Monberg, Marco Donia, Inge Marie Svane, Wim van Harten, John Haanen & Valesca P. Retel (2024) - Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial - Journal for ImmunoTherapy of Cancer, 12 (3) - doi: 10.1136/jitc-2023-008372 - [link]
- Julie M. Vancoppenolle, Nora Franzen, Simone N. Koole, Valesca P. Retèl & Wim H. van Harten (2024) - Differences in time to patient access to innovative cancer medicines in six European countries - International Journal of Cancer, 154 (5), 886-894 - doi: 10.1002/ijc.34753 - [link]
- Ruby M. van Stein, Florine J. Hendriks, Valesca P. Retèl, Cor D. de Kroon, Christianne A.R. Lok, Gabe S. Sonke, Kelly M. de Ligt & Willemien J. van Driel (2023) - Health state utility and health-related quality of life measures in patients with advanced ovarian cancer - Gynecologic Oncology Reports, 50 - doi: 10.1016/j.gore.2023.101293 - [link]
Health Economics Organisation European Cancer Inst
- Start date approval
- September 2021
- End date approval
- December 9999
- Place
- BRUSSEL
- Description
- Coordinator werkgroep
KWF
- Start date approval
- September 2021
- End date approval
- December 9999
- Place
- ROTTERDAM
- Description
- Lid beoordelingscommissie
NKI-AVL Amsterdam
- Start date approval
- September 2021
- End date approval
- December 9999
- Place
- AMSTERDAM
- Description
- Hoofd afdeling Health Technology Assessment
ZonMW
- Start date approval
- September 2021
- End date approval
- December 9999
- Place
- DEN HAAG
- Description
- Lid beoordelingscommissie
Master Thesis HEPL
- Level
- master
- Year Level
- master
- Year
- 2024
- Course Code
- GW4555M
Master Thesis HE
- Year Level
- master, master
- Year
- 2024
- Course Code
- GW4592M
Module Knowledge
- Level
- bachelor 2
- Year Level
- bachelor 2
- Year
- 2024
- Course Code
- GW205K
